Published last week separately 2 teams - one from Japan and one from Sloan Kettering used iPS and hES each that produce dopamine to treat Parkinson's via implanting the cells into subject brains - thus far no major adverse outcomes and some efficacy in Phase I/II trials.
... Here, we report...